AKRO akerotx.com Net earnings per share for the last 12 months

Public company logo of Akero Therapeutics (AKRO)

The annual net income per share reflects the financial dynamics of Akero Therapeutics (AKRO), where the -3.75 level indicates the status of the parameter. The business relies on outsourced manufacturing, depending on external suppliers. The strategy is based on establishing a standard of care for liver fibrosis, although a critical focus on a single drug leaves the company vulnerable to clinical trial results.

AKRO (Akero Corp) Net earnings per share (EPS TTM) history from 07/04/2022 to 12/20/2025

Analytical breakdowns and data insights for company Akero Corp (AKRO)

- stock price and consensus target price:
Fundamental company valuation:Akero Therapeutics, Inc. (AKRO)
Mass-produced product of Akero Therapeutics Inc

To minimize investment risks, it is necessary to monitor the stability of specific returns while excluding the impact of volatility in the number of securities. By analyzing the rolling annual earnings per share, an investor assesses the net financial result divided by the number of shares, which is critical for Akero Therapeutics (AKRO) given its focus on the organic development of an NASH drug without employing merger and acquisition strategies.

Competitors of Akero Therapeutics

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|MTSR (Metsera Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MoonLake Immunotherapeutics|Net earnings per share (EPS TTM) CRNX|Earnings per share for the last twelve months NAMS (NewAmsterdam Pharma Company)|Earnings per share for the last twelve months soleno.life SLNO|Amicus Corp (FOLD) - Net earnings per one share for the last twelve months|ETNB - Earnings per share for the last twelve months|AGIO: Earnings per share for the last twelve months|GPCR: Net earnings per share (EPS TTM)|MDXG - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Rezolute Bio|Lexicon Corp (LXRX) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months mbxbio.com (MBX)|Net earnings per share (EPS TTM) altimmune.com (ALT)|Net earnings per share (EPS TTM) AARD (aardvarktherapeutics.com)|Net earnings per share for the last four quarters Sagimet Biosciences Inc. (SGMT)|BioAge Labs, Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Biomea Fusion Corp BMEA|QNCX: Net earnings per share (EPS TTM)|Fractyl Health, Inc. (GUTS) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months VTVT|Agape ATP Corporation - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PLUR|SYBX - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) LPCN (lipocine.com)|Net earnings per share (EPS TTM) Matinas BioPharma MTNB|SPRB: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months Galecto Corp|CTCX (Carmell Corp) - Net earnings per share for the last 12 months|Lumos Pharma Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS